Jupiter Neurosciences Files 8-K on Material Agreement

TL;DR

JUPITER NEUROSCIENCES (JUPITER) just filed an 8-K for a material definitive agreement, likely a new debt or financing deal.

AI Summary

On November 15, 2024, Jupiter Neurosciences, Inc. entered into a material definitive agreement, likely a financing or debt arrangement, as indicated by the filing of a Form 8-K. This agreement creates a direct financial obligation for the company. The filing also includes financial statements and exhibits related to this event.

Why It Matters

This filing indicates Jupiter Neurosciences has entered into a significant financial commitment, which could impact its future operations and financial health.

Risk Assessment

Risk Level: medium — Entering into new financial obligations can introduce financial risk, especially for companies in the pharmaceutical sector.

Key Players & Entities

• JUPITER NEUROSCIENCES, INC. (company) — Registrant
• November 15, 2024 (date) — Date of earliest event reported
• Delaware (jurisdiction) — State of Incorporation
• 001-41265 (filing_id) — SEC File Number
• 1001 North US HWY 1 , Suite 504 Jupiter , Florida 33477 (address) — Principal Executive Office Address

FAQ

From the Filing

0001493152-24-046734.txt : 20241119 0001493152-24-046734.hdr.sgml : 20241119 20241119123105 ACCESSION NUMBER: 0001493152-24-046734 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20241115 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241119 DATE AS OF CHANGE: 20241119 FILER: COMPANY DATA: COMPANY CONFORMED NAME: JUPITER NEUROSCIENCES, INC. CENTRAL INDEX KEY: 0001679628 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 474828381 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41265 FILM NUMBER: 241474557 BUSINESS ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 BUSINESS PHONE: (561) 406-6154 MAIL ADDRESS: STREET 1: 1001 NORTH US HWY 1 STREET 2: SUITE 504 CITY: JUPITER STATE: FL ZIP: 33477 FORMER COMPANY: FORMER CONFORMED NAME: Jupiter Orphan Therapeutics, Inc. DATE OF NAME CHANGE: 20160713 8-K 1 form8-k.htm false 0001679628 0001679628 2024-11-15 2024-11-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): November 15, 2024   JUPITER NEUROSCIENCES, INC. (Exact Name of Registrant as Specified in Its Charter)   Delaware   001-41265   47-4828381 (State or Other Jurisdiction of Incorporation)   (Commission File Number)   (IRS Employer Identification No.)   1001 North US HWY 1 , Suite 504 Jupiter , Florida   33477 (Address of Principal Executive Offices)   (Zip Code)   (561) 406-6154 (Registrant’s Telephone Number, Including Area Code)   N/A (Former Name or Former Address, if Changed Since Last Report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered None   -   -   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐             Item 1.01 Entry into a Material Definitive Agreement.   On November 15, 2024, Jupiter Neurosciences, Inc., a Delaware corporation (the “Company”), entered into an agreement (the “Tenth Amendment”) with Puritan Partners LLC, a New York limited liability company (“Puritan Partners”), to amend (i) that certain Securities Purchase Agreement, dated as of April 11, 2022, between Puritan Partners and the Company (as amended, supplemented